產(chǎn)品詳情
簡單介紹：
Anti-AADAC抗體產(chǎn)品質(zhì)量穩(wěn)定，實驗效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-AADAC抗體用于**組化實驗,WB實驗,相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-AADAC
Cat. Number:
Anti-AADAC抗體KL-11384R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
The assembly of very-low-density lipoproteins (VLDLs) in the secretory apparatus of the hepatocyte relies on the mobilization Anti-AADAC抗體of triacylglycerol (TAG) from the cytosolic pool by lipolysis and re-esterification. However, some of the re-esterified TAG products are returned to the cytosolic pool in the liver, which protects vulnerable body tissues from excess lipotoxic non-esterified fatty acids in the plasma. Some of the lipases involved in this process include arylacetamide deacetylase (AADAC) and its related proteins AADACL1 and AADACL2. AADAC, a single pass type II membrane protein of the endoplasmic reticulum, is expressed in hepatocytes, intestinal mucosal cells, pancreas and adrenal gland. It plays an important role in the metabolic activation of arylamine substrates to ultimate carcinogens. AADACL1 hydrolyzes the metabolic intermediate 2-acetyl monoalkylglycerol, and its inactivation results in disruption of ether lipid metabolism in cancer cells and impaired cell migration and tumor growth.
Also known as:
AAAD_HUMAN; Aada;Anti-AADAC抗體 Aadac; Arylacetamide deacetylase (esterase); Arylacetamide deacetylase; CES5A1; DAC.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Pig, Cow, Horse, Rabbit, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human AADAC (228-273aa).
●
Predicted Molecular Weight: 46kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 Anti-AADAC抗體ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working Anti-AADAC抗體dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working Anti-AADAC抗體dilutions must be determined by the end user.
kl222Bo01 干擾素β(IFNβ)多克隆抗體 Polyclonal Antibody to Interferon Beta (IFNb)
kl222Ca01 干擾素β(IFNβ)多克隆抗體 Polyclonal Antibody to Interferon Beta (IFNb)
kl222Eq01 干擾素β(IFNβ)多克隆抗體 Polyclonal Antibody to Interferon Beta (IFNb)
kl222Ga01 干擾素β(IFNβ)多克隆抗體 Polyclonal Antibody to Interferon Beta (IFNb)
kl222Hu01 干擾素β(IFNβ)多克隆抗體 Polyclonal Antibody to Interferon Beta (IFNb)
kl222Mu01 干擾素β(IFNβ)多克隆抗體 Polyclonal Antibody to Interferon Beta (IFNb)
kl222Po01 干擾素β(IFNβ)多克隆抗體 Polyclonal Antibody to Interferon Beta (IFNb)
kl222Ra01 干擾素β(IFNβ)多克隆抗體 Polyclonal Antibody to Interferon Beta (IFNb)
kl222Si01 干擾素β(IFNβ)多克隆抗體 Polyclonal Antibody to Interferon Beta (IFNb)
kl223Bo01 白介素1受體拮抗劑(IL1RA)多克隆抗體 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA)
kl223Ca01 白介素1受體拮抗劑(IL1RA)多克隆抗體 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA)
kl223Eq01 白介素1受體拮抗劑(IL1RA)多克隆抗體 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA)
kl223Hu01 白介素1受體拮抗劑(IL1RA)多克隆抗體 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA)
kl223Mu01 白介素1受體拮抗劑(IL1RA)多克隆抗體 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA)
kl223Po01 白介素1受體拮抗劑(IL1RA)多克隆抗體 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA)
kl223Ra01 白介素1受體拮抗劑(IL1RA)多克隆抗體 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA)
kl223Rb51 白介素1受體拮抗劑(IL1RA)多克隆抗體 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA)
kl223Si01 白介素1受體拮抗劑(IL1RA)多克隆抗體 Polyclonal Antibody to Interleukin 1 Receptor Antagonist (IL1RA)
kl224Hu01 基質(zhì)金屬蛋白酶11(MMP11)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 11 (MMP11)
